Stockscreener 앱 받기
34.41
0.20%
-0.07
시간 외 거래:
35.02
0.61
+1.77%
Harrow Inc 주식(HROW)의 최신 뉴스
HROW: Analyst HC Wainwright & Co. Reiterates 'Buy' with $70 Targ - GuruFocus
Harrow's (HROW) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Nomura Downgrades Harrow Health, Inc. (HROW) to Neutral March 18, 2026 - Meyka
Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting - Bitget
Harrow outlines $350M–$365M 2026 revenue goal as sales force expansion and pipeline advances fuel momentum - MSN
HROW: BTIG Reiterates Buy Rating with $63 Price Target | HROW St - GuruFocus
Harrow (NASDAQ:HROW) Given Buy Rating at BTIG Research - MarketBeat
Penn Capital Management Company LLC Makes New Investment in Harrow, Inc. $HROW - MarketBeat
Eye drug studies on dry eye and cataract surgery headed to DC stage - Stock Titan
EnerQuest expansion in Essex County to bring jobs, shift production from U.S. - CBC
Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market (NASDAQ:HROW) - Seeking Alpha
Cantor Fitzgerald Initiates Coverage of Harrow (HROW) with Overweight Recommendation - MSN
EnerQuest in Harrow gets support for re-shoring manufacturing - Sarnia News Today
307,337 Shares in Harrow, Inc. $HROW Bought by Luxor Capital Group LP - MarketBeat
Harrow: why this fast-growing eye-care pharma stock is worth a look - Finimize
Braidwell LP Decreases Stock Position in Harrow, Inc. $HROW - MarketBeat
Assessing Harrow (HROW) Valuation After Strong Revenue Growth And TRIESENCE Phase 3 Progress - Sahm
Harrow, Inc. (NASDAQ:HROW) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Harrow (HROW) Is Down 6.5% After Raising 2026 Guidance And Advancing TRIESENCE To Phase 3 - simplywall.st
Daniel Kaufman holds 1.878M Harrow shares (HROW) — 5.04% reported - Stock Titan
Harrow Health Projects Robust Growth After Strong 2025 - The Globe and Mail
Harrow Health at Leerink Global Healthcare Conference: Strategic Growth Focus - Investing.com
Harrow (HROW) Q4 2025 Earnings Call Transcript - AOL.com
HROW: Record growth and expanding ophthalmic portfolio drive optimism for future launches - TradingView
Harrow (NASDAQ: HROW) furnishes March 2026 corporate investor presentation - Stock Titan
Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Expansions - Investing.com Canada
Harrow Inc (HROW) Q4 2025 Earnings Call Highlights: Record Reven - GuruFocus
HARROW INCHROW 8 5/8 04/30/26 (HROWL) Earnings History & Surprises - ChartMill
Is Harrow Inc. stock a top pick in earnings seasonTrade Performance Summary & Safe Entry Point Alerts - Naître et grandir
Harrow, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:HROW) 2026-03-06 - Seeking Alpha
Has The Recent Slide In Harrow (HROW) Opened A Valuation Opportunity For Investors - simplywall.st
HC Wainwright Issues Negative Forecast for Harrow Earnings - MarketBeat
Buy or Sell Harrow Stock? - Trefis
A Look At Harrow (HROW) Valuation After Mixed Q4 Results And 2026 Profitability Concerns - Yahoo Finance
A Look At Harrow (HROW) Valuation After Q4 2025 Earnings Miss And Raised 2026 Spending Plans - simplywall.st
HC Wainwright Has Pessimistic Outlook of Harrow Q3 Earnings - MarketBeat
Harrow (NASDAQ:HROW) Rating Lowered to "Strong Sell" at Zacks Research - MarketBeat
Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference - The Globe and Mail
H.C. Wainwright raises Harrow Health stock price target to $70 By Investing.com - Investing.com UK
Harrow stock stabilizes after major Tuesday drop - Nashville Post
Harrow Inc (HROW) Trading 4.78% Higher on Mar 4 - GuruFocus
Cantor Fitzgerald lowers Harrow Health stock price target to $91 - Investing.com
Cantor Fitzgerald Lowers Harrow (NASDAQ:HROW) Price Target to $91.00 - MarketBeat
These Analysts Revise Their Forecasts On Harrow Following Q4 Results - Benzinga
Harrow (HROW): Today's Analyst Rating and Price Target Update | - GuruFocus
Harrow (NASDAQ:HROW) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Harrow Health, Inc. (NASDAQ:HROW) Q4 2025 Earnings Call Transcript - Insider Monkey
HROW: HC Wainwright & Co. Raises Price Target, Maintains Buy Rat - GuruFocus
Does Harrow’s (HROW) TRIESENCE Cataract Trial Redefine Its Dropless Eye Care Strategy? - simplywall.st
H.C. Wainwright raises Harrow Health stock price target to $70 - Investing.com
Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade) (NASDAQ:HROW) - Seeking Alpha
Harrow (HROW) -28%: 2026 Guidance Disappoints Market - Trefis
Would You Still Hold Harrow Stock If It Fell Another 30%? - Trefis
With Harrow Stock Sliding, Have You Assessed The Risk? - Trefis
Harrow 2026 slides: ophthalmic firm targets $357M revenue amid stock decline - Investing.com
HROWHarrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits - ADVFN Ltd
Harrow (HROW) Projects Strong Growth with Expanding Ophthalmic P - GuruFocus
Opaleye-managed account sells Harrow (HROW) shares at $54.18 in Form 4 - Stock Titan
William Blair reiterates Harrow Health stock rating on ophthalmic growth - Investing.com
Harrow Shares Collapse, Another Opportunity? (NASDAQ:HROW) - Seeking Alpha
Notable Two Hundred Day Moving Average CrossHROW - Nasdaq
Why Is Eye-Disease-Focused Harrow Stock Falling Today? (UPDATED) - Benzinga
2.02%
0.77%
자본화:
|
볼륨(24시간):